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We report the amino acid sequence of CAP37, a human neutrophil granule protein with antibacterial and rnon~~-s~~c chemotactic activity. 
CAP37 is a single-chain protein consisting of 222 amino acid residues. It has three N-glycosylation sites, at Asn residues 100, 114 and 145. Some 
species of CAP37 are glycosylated at all three sites; some at Asn-114 alone, others at Asn-114 and Asn-110 or Am-145 CAP37 has 45% sequence 
identity to human neutrophil elastase, and 30-37s identity to several other granule serine proteinases. Despite these similarities, CAP37 is not 
a serine proteinase because the active site residues erine and histidine are replaced. 
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1. INTRODUCTION 
We report here the primary amino acid sequence of a 
monocyte-specific chemotactic, cationic protein 
originally isolated from human neutrophil (PMN) 
granules [1,2] owing to its killing of Gram-negative 
bacteria. We named it CAP37 (cationic antimicrobial 
protein of M, 37 kDa). Cationic proteins from human 
PMN such as BPI/CAPS7/BP [4,5], cathepsin G f&7], 
the defensins [S], and CAP37/azurocidin [1,3,9,10] 
have been regarded as oxygen-independent anti- 
infective PMN components. However, we recently 
showed that CAP37 has primary chemotactic action on 
monocytes. This suggests it has another, perhaps more 
important role in defensive in~ammation, specifically 
recruiting monocytes as it is released uring inflamma- 
tion and contributing to the influx of monocytes during 
the second wave of inflammation. 
The amino acid sequence of CAP37 was undertaken 
to deduce any relationships that may exist between its 
structure and known functions. In this report we pre- 
sent the complete amino acid sequence of CAP37 as 
determined by protein sequencing. 
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2. EXPERIMENTAL 
Sequenal grade chemicals for amino acid analysis, protein sequenc- 
ing and HPLC purification were from Applied Biosystems Inc. Se- 
quencing grade trypsin, endoproteinase Asp-N and N-glycosidase- 
F (EC 3.2.2.18) were from Boehringer Mannheim Biochemicals. 
Crystalline porcine pepsin was from Sigma Chemicals. All other 
chemicals were of analytical grade. Reduced-alkylated CAP37 was 
prepared by reduction of the native CAP37 [2] with 2-mercapto- 
ethanol in 6 M guanidine hydrochlo~de followed by alkylation of the 
reduced protein with 4-vinyl pyridine and HPLC-des~ting, yielding 
PE-CAP37 Ill]. 
Cleavage of PE-CAP37 and the native CAP37 with trypsin and en- 
doproteinase Asp-N was done in 0.1 M Tris-HCl buffer, pH 8.0, 1 M 
guanidine hydrochloride (E/S= 1:20 to l:lOO, w/w, at 3O”C, 10-20 
h). Cleavage of PE-CAP37 with pepsin was done in 0.01% aqueous 
TFA (E/S= 1:50, 3O”C, 0.5 h). The resulting digests were acidified 
with TFA and the component peptides separated by HPLC. The 
purified glycopeptides DS and T9 (50 pmol) were treated with N- 
glycosidase-F (1 pmol) in 50 pl of 0.1 M sodium phosphate buffer, pH 
7.2, 1 M guanidine hydrochloride, 10 mM EDTA-Nar (30°C 24 h). 
At the end of the reaction, the deglycosylated peptides (D5F and T9F) 
were absorbed (at 25”C, 2 h) onto three pieces (2x4 mm) of Im- 
mobilon P membrane (Millipore Co.). The membranes were washed 
several times with water and directly subjected to Edman degrada~on 
[12]. Treatment of native CAP37 (1 pg) with N-glycosidase-F was per- 
formed in 10 $ of 0.1 M sodium phosphate buffer, pH 7.2, 10 mM 
EDTA-Na2 (E/S= 1:150, w/w, 3O”C, 40 h). 
Purification of peptides was done by microbore reverse-phase 
HPLC on an Applied Biosystems Model 130A Micro Separation 
System equipped with a microbore LC flow cell and 0.005 inch I.D. 
tubing. Applied Biosystems Aquapore RP-300 C8 or Aquapore 
OD-300 Cl8 siiica columns (1 x 250 mm) were equilibrated in 0.1% 
(v/v) aqueous TFA and developed at flow rates of 50-80 )dl/min using 
a linear gradient (0.5% per min) of acetonitrile/water/TFA 
(4:1:0.004 v/v/v). Material absorbing at 214 nm was manually col- 
lected and stored at - 20°C. Rechromatography of some fractions in 
a second solvent system consisting of 2-propanol/acetonitrile/ 
water/TFA (7:2: l:O.OOS) was required before sequencing. Ail samples 
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were sequenced in an Applied Biosystems Model 477A Protein Se- 
quencer with on-line Model 120A PTH Analyzer. Automated Edman 
degradation [13] was done using the manufacturer’s reaction vessel 
cycle PRO-I, with modifi~tions in&ding the use of a higher reaction 
temperature (49°C) and a 30% increase in the delivery time of 
trimethylamine vapors. Cysteine was determined as PTH-S-&(4-pyri- 
dylethyl)Cys. The amino acid composition of certain peptides was 
determined using a Model 420A DerivatizerIl30A PTC Analyzer 
equipped with an on-line hydrolysis unit assembly (Applied 
Biosystems). 
SDS-~i~c~lamide gel ekctrophoresis (SDS-PAGE) was per- 
formed according to the method of Laemmli [14]. All protein samples 
were solubilized in 0.625 M Tris (pH 6.8), 4010 (w/v) SDS, and 1% 
(v/v) 2-mercaptoethanol at 100°C for 5 min and analyzed on a 12.5% 
gel. The proteins were visualized by silver staining . 
3. RESULTS AND DISCUSSION 
The complete sequence of PE-CAP37, as summariz- 
ed in Fig. 1, was determined by analysis of fragments 
generated by cleavage with endopeptidases. All en- 
doproteinase Asp-N peptides (Dl-D8), representing the 
full-length sequence, were recovered. Fragments Dl 
(residues l-58) and D5 (residues %-151), which could 
not be sequenced completely because of their length, 
were subfragmented by trypsin, yielding peptides 
DlTl-DlT4 and D5Tl-D5T4, respectively. Sequenc- 
ing of tryptic (Tl-T12) and peptic (Pl-Pll) peptides 
provided the necessary overlaps and allowed the order 
of the endoproteinase Asp-N peptides to be dete~ined. 
The tryptic peptides T12a and T12b, were identified as 
C-terminal since their C-terminal amino acid residues 
(glycine and proline, respectively), are incompatible 
with the cleavage specificity of trypsin. As further 
proof, two C-terminal peptides, each with a different 
C-terminus amino acid, were isolated in approximately 
the same quantities from peptic (peptides Pl la,b) and 
endoproteinase Asp-N (peptides D8a,b) digests. Thus, 
the mature (active) CAP37 was determined to be a 
single chain polypeptide, composed of either 221 or 222 
residues, and heterogeneous at the c~boxy-te~inus. 
CAP37 contains eight cysteine residues which are 
found at positions corresponding to those in elastase, 
complement factor D and chymotrypsin [ 15,161. Dur- 
ing HPLC purification of the tryptic digest of native 
CAP37, peptides T3 and T4 co-migrated as an 
equimolar mixture of both; however, after reduction 
and alkylation, they migrated separately and were 
recovered as individual entities. This indicates that, in 
the native protein, Cys-26 and Cys-42 form a disulfide 
bridge. Peptide T9, containing Cys-154 and Cys-160, 
was isolated both from native and reduced-alkylated 
CAP37 as a single entity indicating that, in CAP37, 
Cys-154 and Cys-160 are either linked to each other 
through a disulfide bond or that they are in a free state. 
The oxidation state and pairing of the remaining Cys 
residues is currently being examined, and preliminary 
evidence indicates that the remaining two in- 
tramolecular disulfide bonds between Cys-123-181, and 
Cys-171-l% are also conserved. 
Fig. 1. Amino acid sequence and composition of CAP37. The amino 
acid sequence of the p~dylethylated protein was determined by 
automated Edman degradation of intact protein, and of its fragments 
generated by endoproteinase Asp-N (D), trypsin (T) and pepsin (P). 
Dashed lines indicate positions in sequencer uns where further 
sequence information was either not obtainable or unnecessary. The 
sites of N-glycosylation, Asn-100, Asn-114 and Asn-145 (*), and the 
positions of residues equivalent o the catalytic residues of serine 
proteinases (+ ) are indicated. 
‘Values in parentheses represent previously publish~ amino acid 
composition (%‘o total amino acids) [l]. 
CAP37 contains three potential N-glycosylation sites 
of the - Asn(CHO)-X-Thr - type. These sites, 
residues 100, 114 and 145 (Fig. l), were identified in the 
following way: (i) on sequencing of fragments D5, 
D5T1, D5T4, T6 and T9, no PTH-amino acid could be 
recovered or identified in positions 100, 114 and 145 of 
the CAP37 sequence, suggesting the possibility of N- 
glycosylation; (ii) sequencing of peptides D5 and T9, 
after their exposure to N-glycosidase-F (peptides DSF 
and T9F in Fig. l), yielded PTH-aspartic acid in cycles 
corresponding to residiues 100, 114 and 145, confirm- 
ing that these residues are N-glycosylated asparagines; 
(iii) unglycosylated Asn- 100 and Asn- 145 were found in 
peptides P5 and P7, respectively, showing that CAP37 
also exists as a partially non~ycosylated protein. 
The existence of partially glycosylated or unglycos- 
ylated species of CAP37 is also evidenced by its elec- 
trophoretic and chromatographic behavior, a 37 kDa 
species as reported by our laboratory [1,2], and a 29 
kDa species as observed by others [9, lo]. Two different 
preparations of CAP37 (identity established by a com- 
plete match of the first 20 amino acids), one which 
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Fig. 2. Silver stained SDS-PAGE comparing native CAP37 with N- 
glycosidase-F-treated CAP37. The following samples, 2 cg ‘rainbow’ 
molecular mass markers (Amersham Corp.) in lanes 1, 4 and 8, 1 pg 
native CAP37 migrating at M, 31 and Mr 37 kDa in lanes 2 and 5, 
respectively, N-glycosidase-F-treated CAP37 in lanes 3 and 6, and N- 
glycosidase-F in lane 7, were analyzed on 12.5% SDS-PAGE. The M, 
of the standards are indicated in the figure. The extra band seen at M, 
35.5 kDa in lanes 3 and 6, is N-glycosidase-F. 
migrated at approximately 37 kDa, and the other which 
migrated at approximately 3 1 kDa on SDS-PAGE (Fig. 
2, lanes 2 and 5) were subjected to N-glycosidase-F 
treatment. Following treatment both preparations of 
CAP37 migraterd at approximately 28 kDa (Fig. 2, 
lanes 3 and 6) indicating that the carbohydrate moieties 
may constitute up to 24% of the total mass of the pro- 
tein. 
During the HPLC fractionation of the enzymatic 
digests of CAP37, glycopeptides D5, DSTl , DST4 and 
T9 were each found in several fractions. Sequencing of 
these fractions showed them to be indistinguishable 
from each other. We conclude that these fractions 
represent glycopeptides with the same sequence and dif- 
fering carbohydrate content. 
A search of the GeneBank sequence data library [17] 
reveals that CAP37 as we suggested [II] has its 
strongest homology with human neutrophil elastase 
(45%), and 30-37070 homology with human comple- 
ment factor D, human cathepsin G, rat mast cell pro- 
teinases I and II, and the cytotoxic T-lymphocyte serine 
proteinases. CAP37 and human neutrophil elastase 
(Fig. 3) have 50% identity between residues l-95 and 
residues 123-220. Importantly, these two regions con- 
tain all eight strictly conserved cysteine residues of 
CAP37 and elastase. Also, the disulfide bridges formed 
by four of these, Cys-26 to Cys-42 and Cys-154 to 
Cys-160, have their counterpart in elastase [161, sug- 
gesting that CAP37, like elastase, has a chymotrypsin- 
like type of disulfide pairing. 
A 27-residue segment of CAP37 defined by residues 
96-122 is different from elastase. It contains two N- 
glycosylation sites, Asn-100 and Asn-114, indicating its 
surface location. The Asn-114 site found glycosylated 
without exception lacks a counterpart in elastase and 
other granule serine proteinases suggesting a special 
role, perhaps in intracellular sorting and targeting. In- 
terestingly, the beginning of this segment coincides with 
one of the exon/intron junctions of elastase [ 181, which 
maps between Gln-93 and Leu-94 of the translated 
elastase sequence (Fig. 3), and it is also found in the 
related proteinases, RCMP II and adipsin [19,20]. In 
other serine proteinases, the exon/intron junctions are 
located in the surface areas of these proteins and are 
characterized by high structural divergency [21,22]. It is 
therefore likely that an exon/intron junction is located 
in the same region of the CAP37 gene and could be of 
,“GGRKARP’~OFPFLAslON~GR”FcGGA30LIHARFVMT*AscF~s~NPG~sT”“LGAYDL 
Illll III II II IIIII II lllllI I 11111 I 
IVGGRAARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNL 
10 30 t h 50 
RRRERQSRP~FSISSMSENGYDP*~NLN~~~LLQLDR~A~LTSSVT,L~~PLD~ATV~-A 
III II I I III1 III III I II III I 
SRREPT-RPVFAVQRIFEDGYDPVNLLNDlVlLQL----NGS--ATl------NANVDVA 
70 +90 A * 
130 * 150 
. ..-- GTR------CDVAGWGSQ-RSGGRLSRFPRFVNVTVTPEDQCRPNNVCTGVLTR- 
I I I II I I I I Ill1 II IIII I I 
DLPADGRRLGNGVDCLAMGWGLLGRNRGIASVLQE-LNVTVVTSL-CRRSNVCT~-LVRG 
110 130 * 150 
170 100 210 
R-GGICNGDGGTPLVCEGLAHGVASFSLGPCGRG--PDFFTRVALFRDWlDGVLNNPGP 
I IIIIIllllII I1111 II I III III Ill 
RDAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVADFVNWIDSIID 
fi t 130 210 
Fig. 3. Alignment of primary structures of CAP37 (top line) and human neutrophil elastase [16]. The identical residues are connected by vertical 
bars (I); the gaps ( - ) are inserted in order to obtain maximum sequence identity. Positions of the catalytic residues (+ ) and of the glycosylation 
sites (*) in both proteins, and positions of introns (^) of the elastase gene [18] are indicated. 
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evolutional impo~ance for the functions differentia- 
tion of CAP37. 
The most critical sequence differences between 
CAP37 and elastase involve the catalytic residues. 
His-41, Asp-88 and Ser-173 in neutrophil elastase, are 
strictly conserved in all serine proteinases [23]. An 
equivalent catalytic aspartic acid Asp-89, is found in 
CAP37; however, the histidine and serine catalytic 
residues, are substituted by se&e-41 and glycine-175. 
These findings explain the lack of serine proteinase 
function in CAP37 111,241. 
Significantly, the segments of the CAP37 sequence in 
the immediate vicinity of Ser-41 and Gly-175 are iden- 
tical to, or highly conserved with, elastase, and include 
some of the residues which form the primary specificity 
pocket, Sl. Ile-170, Gly-173, Ala-189 and Asp-201 of 
CAP37 have their topological counterparts in Val-168, 
Gly-171, Ala-187 and Asp-201 of elastase. Asn-172 and 
Ser-191 of CAP37 have their equivalents in Phe-170 
and Val-190 of elastase, suggesting that Sl in CAP37 is 
more polar than in elastase. Asp-174 of CAP37 has its 
equivalent in Asp-172 of elastase, a residue forming a 
salt bridge with Ile- 1, as found in other trypsin-like pro- 
teinases [23,26,27]. One might therefore expect a 
similar role for Asp-174 and Ile-I in CAP37. Thus, even 
though the serine proteinase catalytic apparatus of 
CAP37 has been abrogated, the overall spatial arrange- 
ment of its primary substrate binding cleft seems to be 
preserved. 
Analysis of the gene structure of CAP37 will con- 
tribute to the understanding of its evolutionary rela- 
tionship to mammalian serine proteinases. In the 
neutrophil elastase, adipsin and RMCPII proteinase 
genes [18,19,20], the codons for catalytic residues His, 
Asp and Ser are located on separate xons [ 181. Assum- 
ing the same exon/intron pattern for CAP37, it is likely 
that the present structure of CAP37 was formed by 
evolutionary processess involving excission of its two 
catalytic residues, followed by gene duplication of these 
exons and recombination. 
Are the structure of CAP37 derived from its amino 
acid sequence and its bactericidal and chemotactic ac- 
tivity related? Overall the molecule is basic, having 23 
positively charged residues as opposed to 15 acidic 
residues (Fig. 4). The amino terminus up to residue 70 
has 11 basic residues, with four of them being present in 
the first 10 amino acids. The next section of the mole- 
cule (amino acids 78 to 118) shows a preponderate of 
acidic residues (6 acidic, 1 basic) followed by a second 
basic region ending at amino acid 142, thereafter the 
COOH terminus shows an alternating pattern of basic 
and acidic residues. 
The basic Gino-terminus may enhance electrostatic 
interaction between CAP37 and the negatively charged 
lipid A of CAP37 sensitive bacteria such as Salmonella. 
The binding of BPIKAP57, another cationic protein 
to Salmonella, is dependent on both electrostatic and 
+ 
Charge 1 i i iP 
v 
50 100 150 200 
Fig. 4. Plot of hydrophilicity and charge distribution of CAP37. 
Hydrophilic residues are designated as positive, and hydrophobic 
residues as negative. Basic residues are represented as positively 
charged and acidic residues as negative. 
hy~ophobi~ bindings [28-301. Recent evidence shows 
the N-terminal pentapeptides IIGGR of cathepsin G 
[31], and IVGGR of elastase, the latter of which is iden- 
tical to the N-terminus of CAP37, to possess antibiotic 
activity [32]. 
The hydrophilicity plot of mature CAP37 protein us- 
ing the method of Hopp and Woods 1331 indicates a 
protein with alternating hydrophobic and hydrophilic 
domains, with one extended hydrophobic stretch be- 
tween amino acids 26 and 58. The three highest points 
of hydrophilicity are from residues 61 to 66, 5 to 10, 
and 150 to 156. Proteins such as a-casein, /3-casein, and 
been venom mellitin, which are cationic and contain 
hydrophobic sections show chemotactic activity. It is 
believed that these molecules are taken up more avidly 
into lipid bilayers than other proteins, enhancing their 
affinity for cell membranes and subsequent chemotactic 
binding [34]. The same may apply to CAP37, a cationic 
poly~ptide with alternating hydrophobic stretches. 
Comparison of the CAP37 sequences with known 
monocyte chemoattractants uch as fMLP, MCP-I, 
and the defensins hows no similarities. The availability 
of the covalent structure will be helpful in defining these 
mechanisms as well as to allow synthesis of phar- 
ma~ologica~y useful compounds. 
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